Compare JAZZ & TTMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | TTMI |
|---|---|---|
| Founded | 2003 | 1978 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 10.1B |
| IPO Year | 2007 | 2000 |
| Metric | JAZZ | TTMI |
|---|---|---|
| Price | $202.63 | $156.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $217.57 | $127.25 |
| AVG Volume (30 Days) | 835.7K | ★ 1.7M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 211.11 |
| EPS | N/A | ★ 1.68 |
| Revenue | $1,618,693,000.00 | ★ $2,906,345,000.00 |
| Revenue This Year | $6.22 | $18.60 |
| Revenue Next Year | $7.68 | $16.91 |
| P/E Ratio | ★ N/A | $80.46 |
| Revenue Growth | N/A | ★ 18.98 |
| 52 Week Low | $105.00 | $23.72 |
| 52 Week High | $207.48 | $149.00 |
| Indicator | JAZZ | TTMI |
|---|---|---|
| Relative Strength Index (RSI) | 58.80 | 73.17 |
| Support Level | $159.78 | $87.36 |
| Resistance Level | $207.48 | N/A |
| Average True Range (ATR) | 5.08 | 9.84 |
| MACD | -0.30 | 2.41 |
| Stochastic Oscillator | 63.40 | 65.47 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
TTM Technologies Inc manufactures technology products, including mission systems, RF components, RF/microwave assemblies, and advanced interconnect products such as PCBs and substrates. It operates through three segments: A&D, Commercial, and RF&S Components. The A&D segment supports aerospace and defense missions with PCBs, assemblies, microelectronics, and integrated systems. The Commercial segment, generating the majority of revenue, serves automotive, medical, industrial, and data center markets. The RF&S Components segment provides TTM-designed RF components and COTS products. The Company's revenues come from PCBs, engineered systems, and long-term contracts for intelligence, surveillance, and communications solutions.